CS MEDICA A/S (”CS MEDICA” or the ”Company”) hereby announces that the Danish Parliament has voted unanimously, to make the current Pilot Programme for medical cannabis a permanent scheme. Companies’ opportunities to produce medical cannabis become permanent, while doctors’ ability to prescribe cannabis drugs is extended by four years.

The Danish Parliament voted unanimously, 102-0, to make the current pilot program for medical cannabis a permanent scheme. In doing so, companies will be able to manufacture cannabis for medical use on a permanent basis. In addition, doctors are now able to prescribe medical cannabis to patients for an additional four years.

CS MEDICA operates within the pharmaceutical area of business focusing on cannabis and cannabinoids and is committed to developing and manufacturing medical device products containing cannabinoids. The new agreement affects the entire Danish medical cannabis industry and the ecosystem. Regulatory reforms or changes in political situations like these have the potential to affect CS MEDICA both directly and through the Company’s partners. The decision to make Danish manufacturing of medical cannabis permanent will move the industry in a positive direction and potentially stimulate further investments. In addition, CS MEDICA believes the news is relevant for the launch of future product lines.

“We are glad that the Danish Parliament has expressed their support for the cannabis industry in Denmark. This regulation reflects positively on our business as these regulatory reforms will increase the awareness of medical cannabis and hopefully allow the industry to grow even more. We feel confident that this news will have a positive impact on the industry and market in which we operate while also decreasing a risk factor for our company,” says Lone Henriksen, CEO of CS MEDICA.

For more information about CS MEDICA, please contact:
Lone Henriksen, CEO
Phone: + (45) 71 20 30 47
Email: lh@galaxapharma.com
Website: https://www.cs-medica.com/

CS MEDICA A/S is a Danish medico cannabis company founded in 2011. CS MEDICA is committed to developing, manufacturing, and commercializing over-the-counter (OTC) medical device products containing cannabinoids. The Company runs its business through the two fully-owned subsidiaries, Galaxa Pharma A/S (distributor and representative of foreign manufacturers in the Nordic, registered medical device product distributor) and CanNordic A/S (Medical device developer and seller (BtB), registered medical device product manufacturer). CS MEDICA distributes products across the European borders and is headquartered in Copenhagen, Denmark.

The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information about CS MEDICA cs-medica.com.

Tags: